Interim Data from ImmunoNET Study Demonstrate NP137 Potential to Overcome Resistance to Immune Checkpoint Inhibitors
Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025
April 25th, 2025
Lyon, France and Geneva, Switzerland — NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of therapeutics targeting Netrin-1, today announced positive interim results from the ongoing ImmunoNET Phase II trial of its lead candidate NP137. The multicenter, open-label, proof of concept study is designed to evaluate the clinical and biological activity of NP137 as an add-on therapy in patients with advanced or metastatic Head & Neck Cancer and Non-Small Cell Lung Cancer (NSCLC) who have progressed under standard immunotherapies. The interim analysis met both the primary and key secondary endpoints in secondary refractory patients. Such analysis confirms NP137 excellent safety profile and its potential to overcome secondary resistance to leading immunotherapies. Clinical benefits were observed in half of thepatients with Head & Neck and NSCLC cancers who had previously progressed under approved immunotherapy. “These interim results mark a major milestone in our mission to develop drugs that overcome therapy resistance,” said Patrick Mehlen, CEO of NETRIS Pharma. “We are excited by the potential of NP137 to restore patients sensitivity to immunotherapy-based treatments and to deliver a new treatment solution for patients with limited options.”
Upcoming Data Presentations
Comprehensive study design and interim results will be presented at two of the world’s leading oncology congresses: the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress in 2025, underscoring the global significance of these findings.